Am­gen comes up with $1.5B pack­age to part­ner with Cy­tomX on a pre­clin­i­cal Pro­body ap­proach to can­cer

About six months af­ter Bris­tol-My­ers Squibb forked out $200 mil­lion in cash to ex­pand its work with Cy­tomX $CT­MX and the pre­ci­sion bi­ol­o­gy tech found on its Pro­body an­ti­body plat­form, Am­gen has signed off as the biotech’s lat­est mar­quee col­lab­o­ra­tor.

Just as Bris­tol-My­ers $BMY was drawn to Pro­bod­ies for a shot at a new and bet­ter CT­LA4, among oth­er things, Am­gen $AMGN is com­ing in for a T-cell en­gag­ing bis­pe­cif­ic tar­get­ing the Epi­der­mal Growth Fac­tor Re­cep­tor (EGFR), a high-val­ue tar­get ex­pressed on mul­ti­ple can­cer types. They’re build­ing on the biotech’s pre­clin­i­cal work on an EGFRx­CD3 pro­gram.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.